Drug Trial Radar · NCT04015024
A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients
Last checked: Nov 19, 2026Latest source record: Jul 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 2019
Primary completion
Apr 2021
Study completion Jun 2021
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients will receive oral SKLB1028 for 28 days as a course of treatment, and then to evaluate the side effects,tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.
Conditions
- Acute Myeloid Leukemia
Interventions
SKLB1028 150mg bidDrug
150mg oral administration twice a day
SKLB1028 200mg bidDrug
200mg oral administration twice a day
SKLB1028 300mg qdDrug
300mg oral administration once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total remission rate (ORR)Time frame: Evaluation at the end of each cycle(a cycle is 28 days) of administration and at the end of the study (assessed up to approximately 24 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital,Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.